Pravastatin
- Generic Name
- Pravastatin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H36O7
- CAS Number
- 81093-37-0
- Unique Ingredient Identifier
- KXO2KT9N0G
- Background
Pravastatin is the 6-alpha-hydroxy acid form of mevastatin. Pravastatin was firstly approved in 1991 becoming the second available statin in the United States. It was the first statin administered as the active form and not as a prodrug. This drug was developed by Sankyo Co. Ltd.; however, the first approved pravastatin product was developed by Bristol Myers...
- Indication
Pravastatin is indicated for primary prevention of coronary events hypercholesterolemic patients without clinical evidence of coronary heart disease. Its use includes the reduction of risk on myocardial infarction, undergoing myocardial revascularization procedures and cardiovascular mortality.
...
- Associated Conditions
- Acute Coronary Events, Cardiovascular Outcomes, Coronary Artery Atherosclerosis, Death, Dysbetalipoproteinemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Hyperlipidemias, Mixed Dyslipidemias, Myocardial Infarction, Myocardial Revascularization, Secondary prevention cardiovascular event, Stroke, Sudden Cardiac Death, Transient Ischemic Attack, Elevation of serum triglyceride levels
- Associated Therapies
- -
Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE)
- Conditions
- Interventions
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 295
- Registration Number
- NCT06494111
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Study to Evaluate the Drug-drug Interaction Potential of BMS-986196 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2023-05-10
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 18
- Registration Number
- NCT05852769
- Locations
- 🇺🇸
ICON plc, Millcreek, Utah, United States
Pravastatin as a Prophylactic to Reduce Endothelial Injury in Pediatric Patients With Elevated Body Mass Index
- Conditions
- Interventions
- First Posted Date
- 2022-09-01
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 30
- Registration Number
- NCT05524246
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
An Observational Study Investigating the Change in Blood Cholesterol With Mevalotin® Tablet Administration in Korean Menopausal Women Aged 50 Years or More Who Require Treatment of Dyslipidemia
- First Posted Date
- 2021-11-15
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 3300
- Registration Number
- NCT05120895
- Locations
- 🇰🇷
Inje University Haeundae Paik Hospital - Site 0031, Busan, Korea, Republic of
🇰🇷Pusan National University Hospital - Site 0033, Busan, Korea, Republic of
🇰🇷Hallym University Medical Center - Chuncheon, Chuncheon, Korea, Republic of
An Observational Study Investigating the Effectiveness of Pravastatin on Renal Function in Korean Dyslipidemic Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2021-11-04
- Last Posted Date
- 2021-11-04
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 2972
- Registration Number
- NCT05107063
- Locations
- 🇰🇷
Dongguk University Ilsan Hospital, Goyang, Korea, Republic of
🇰🇷Daegu Catholic University Medical Center, Daegu, Korea, Republic of
🇰🇷HANIL General Hospital, Seoul, Korea, Republic of
Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2022-06-14
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 27
- Registration Number
- NCT04608344
- Locations
- 🇺🇸
Prism Research, LLC, Saint Paul, Minnesota, United States
Improving Theempowerment in Patients With Severe Breast Fibrosis Radio-induced Treated by Pravastatin : Benefit of e-PROs (Electronic " Patient Reported Outcome ") on Breast-related Quality of Life
- First Posted Date
- 2020-04-22
- Last Posted Date
- 2023-08-23
- Target Recruit Count
- 105
- Registration Number
- NCT04356209
- Locations
- 🇫🇷
ICM Val d'Aurelle, Montpellier, France
Pravastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2020-02-26
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 30
- Registration Number
- NCT04284657
- Locations
- 🇺🇸
Keck School of Medicine of University of Southern California, Los Angeles, California, United States
Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial
- Conditions
- Interventions
- First Posted Date
- 2019-12-09
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- Mayo Clinic
- Registration Number
- NCT04190433
Pravastatin to Prevent Preeclampsia
- Conditions
- Interventions
- First Posted Date
- 2019-05-09
- Last Posted Date
- 2024-07-09
- Target Recruit Count
- 50
- Registration Number
- NCT03944512
- Locations
- 🇺🇸
Magee Women's Hospital of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸University of Texas Medical Branch, Galveston, Texas, United States
🇺🇸Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.